Phase I/Ib; open-label; multicenter; dose-escalation study of the anti-TGF-β monoclonal antibody; NIS793; in combination with spartalizumab in adult patients with advanced tumors.

Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T.

J Immunother Cancer. 2023 Nov 29;11(11):e007353. doi: 10.1136/jitc-2023-007353.

https://pubmed.ncbi.nlm.nih.gov/38030303/